MindRank doses first patient in Phase III trial of AI-designed oral GLP-1 agonist MDR-001
MindRank announced it has dosed the first patient in a Phase III trial of MDR-001, an oral GLP-1 receptor agonist designed using the company's AI platforms. The company says the program used its PharmKG knowledge graph, Molecule Dance protein simulation, and Molecule Pro generative AI with ADMET prediction alongside wet‑lab validation.
